Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

Daryl1689 Jun. 22 at 11:24 PM

$SLS once you block the paid bashers, this board is relatively quiet. Why are they so worried about this ticker?

1 · Reply

TROYTIPTON Jun. 22 at 10:04 PM

$SLS If your Mom, wife or daughter are still hookin' part-time...make sure you ask them for at least half of tonite's proceeds (each Pimp is different, of course) and make sure you have some dry powder for the pre-market FOMO tomorrow...SLS in gonna be insane!!!💸💵🚀😄🔥💰💰🧨💵💵

0 · Reply

Gps_100X_ROI_Potential Jun. 22 at 10:03 PM

$SLS

0 · Reply

TROYTIPTON Jun. 22 at 9:47 PM

$SLS Light those rockets, boys!! BUY....HOLD...GET RICH! ThIs biyatch is gonna go @ss crazy tomorrow l!! Not only a huge run-up....but then a GAMMA SQUEEZE!!! Can you believe it?? It's finally our time!!! Hold your gold!!!

0 · Reply

OnTheBalance Jun. 22 at 9:12 PM

$SLS all the warrants nonsense from the Trolls in Turdistan is pure bunk. Their Bunker has been BUSTED. Here are the current facts, and read the footnote carefully.

3 · Reply

Nasfact Jun. 22 at 8:30 PM

$MRK $ABBV that is quite interesting... More and more I see how $SLS can be worth 70$-120$ but based on other BO's I expect a big increase in share price 20+ before BO which for sure can follow shortly after... And yes all this warrants bla blubb included which simply is relevant or irrelevant depending on announcements... But all speculation for sure! Patience for the patients!

1 · Reply

Nelvestor Jun. 22 at 7:33 PM

$SLS N Bo Q4 or Q1 of next year is most likely. Significamt increase in share price will happen when positive post 80 ebents resultd come in. If you are interested in biotech investing, this is the best place for your money

1 · Reply

Fistful_of_Lithium Jun. 22 at 7:13 PM

$SLS

0 · Reply

Tymetowait Jun. 22 at 6:58 PM

$SLS did they ever state the parameters of the ESPP?

0 · Reply

TheSuper Jun. 22 at 6:57 PM

$SLS BPIQ had $SLS show up on weekly watch lists for phase 2 & 3 catalyst. Good reminder that we are close whether it is next week or next month or Q3. We are close. I will continue to state IMO BO is this year.

0 · Reply

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 20 days ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 4 weeks ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 5 weeks ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 5 weeks ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 7 weeks ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 2 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 2 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 2 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 3 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 4 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 5 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 5 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 5 months ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 6 months ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 6 months ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 7 months ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 7 months ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 7 months ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 8 months ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 8 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 9 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 11 months ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 11 months ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 1 year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 1 year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Jan 25, 2024, 8:45 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

Jan 9, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Jan 4, 2024, 9:01 AM EST - 1 year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Jan 3, 2024, 8:05 PM EST - 1 year ago

SELLAS Life Sciences Announces Proposed Public Offering

Jan 3, 2024, 7:30 AM EST - 1 year ago

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Dec 27, 2023, 8:55 AM EST - 1 year ago

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Dec 21, 2023, 8:15 AM EST - 1 year ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Dec 14, 2023, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

Daryl1689 Jun. 22 at 11:24 PM

$SLS once you block the paid bashers, this board is relatively quiet. Why are they so worried about this ticker?

1 · Reply

TROYTIPTON Jun. 22 at 10:04 PM

0 · Reply

Gps_100X_ROI_Potential Jun. 22 at 10:03 PM

$SLS

0 · Reply

TROYTIPTON Jun. 22 at 9:47 PM

0 · Reply

OnTheBalance Jun. 22 at 9:12 PM

$SLS all the warrants nonsense from the Trolls in Turdistan is pure bunk. Their Bunker has been BUSTED. Here are the current facts, and read the footnote carefully.

3 · Reply

Nasfact Jun. 22 at 8:30 PM

1 · Reply

Nelvestor Jun. 22 at 7:33 PM

1 · Reply

Fistful_of_Lithium Jun. 22 at 7:13 PM

$SLS

0 · Reply

Tymetowait Jun. 22 at 6:58 PM

$SLS did they ever state the parameters of the ESPP?

0 · Reply

TheSuper Jun. 22 at 6:57 PM

0 · Reply

Gps_100X_ROI_Potential Jun. 22 at 6:54 PM

$MRK $ABBV $SLS GPs + Keytruda 18.4 vs 13.8 w Keytruda alone --\-- Elahere bought by $ABBV for $10B based on 16.46 months of median Os Dr. Cohen MRK co-authored this Publication concluding Gps should be combined with CPI's / Keytruda - for multiple solid tumor cancers. that is extremely bullish MedSpeak. - and remember MRK has been waiting for the P3 AML Remission data too - INCOMING ANY DAY NOW - before they'll pay the SLS CEO's $10B Buyout price. -- Its June 22.

0 · Reply

samsha1 Jun. 22 at 6:04 PM

$SLS among other things this is why Sellas will be acquired this year for $100 plus GPS will be the next Keytruda and SLS will be the next Ibrance or more! Examples of Drugs Facing Patent Expiration: Keytruda (Merck): A cancer immunotherapy with $29.5 billion in 2023 sales, will lose patent protection in 2028. Eliquis (Bristol Myers Squibb/Pfizer): A blood thinner, will see patent expiration in 2027 or 2028. Opdivo (Bristol Myers Squibb): An immunotherapy, will lose patent protection in 2026 or 2027. Trulicity (Eli Lilly): A diabetes medication, will expire in 2027. Ibrance (Pfizer): A breast cancer drug, will expire in 2027.

3 · Reply

JRUKUKUK Jun. 22 at 4:19 PM

$SLS As much as I despise them on small cap stocks. Do any of you learned people know why SLS only has monthly options for 2 of the next 6 months? Just out of interest...

1 · Reply

NEWBIGTECH Jun. 22 at 3:50 PM

$SLS Not only $SLS But every stock company and investor will no longer have the sabre rattling state to worry about. You have witnessed "peace through strength.' Few Iranian civilians were killed, no AMERICANS were injured. Maya yes, $DJT THE PEACE PRESIDENT.

1 · Reply

takeshoot Jun. 22 at 2:57 PM

$SLS do you think that current strike of USA on Iran can have some effect on the SLS price?

5 · Reply

KiryuKazama Jun. 22 at 1:30 PM

$SLS the trials have been a massive success u stupid piece of unfiltered dog shit. I hope u get cancer and have to deal with the uncertainty of not having a cure. What a dumb low IQ piece of shit you are

6 · Reply

SLS_4life Jun. 22 at 12:20 PM

$SLS One of these mornings, we'll wake up to a massive gap down after the CEO leaks how the trial is a complete failure. Im betting it'll be tomorrow.

1 · Reply

Notanymore Jun. 22 at 4:40 AM

$SLS The FDA has used the same metrics/approval process for at LEAST the LAST 60 years. Prove me wrong but it’s badly outdated.

1 · Reply

Notanymore Jun. 22 at 3:44 AM

$SLS Look. I am not posting to get high fives. I’ve had enough experience with all considered in the medical field - from all angles that I think I can offer a reasonable opinion. I appreciate all comments to my posts. That’s what discourse is all about… But I will say again… the FDA (in my opinion) is walking a fine line here between continuing this trial vs stopping it and offering GPS to all comers - but STILL RECORDING DATA FOR FUTURE reference. 80 is not set in stone. People’s lives matter and data can still be recorded with current patients in therapy, Safety NOT AN ISSUE EFFICACY - based on all accumulated data indicates a strong pattern with response. Stop the trial FDA … give it to all comers, continue recording data and if it’s a fluke then take it off the market. Easy enough I highly doubt it.

5 · Reply

CEOofstocks Jun. 22 at 3:24 AM

$SLS July is 9 days away. Will 80 come in July? I think so, going to guess July 18th. What's your guess?

2 · Reply

Tymetowait Jun. 22 at 2:52 AM

$SLS I hope the BOD had some important matters to tend to on Friday like a 15b buyout offer. I’ll settle for and SLS009 PR though with a buyout later in August.

0 · Reply

Rafteriffic Jun. 22 at 1:35 AM

$SLS Glad I’m only currently biotech, volatility hedging, and cash.

2 · Reply

Market Cap	153.66M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,186,900
Avg Vol	2,408,592
Day's Range	N/A - N/A
Shares Out	99.78M
Stochastic %K	27%
Beta	2.25
Analysts	Strong Sell
Price Target	$5.83